The board of directors SSY Group Limited announced that the group has obtained the approval for drug clinical trial in relation to the bio-equivalency for Cefdinir Capsules from the China Food and Drug Administration. Cefdinir is an anti-infective agent and a type 6 chemical drug.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.32 HKD | +0.70% |
|
-0.23% | -12.55% |
07:48am | Chinese Regulator OKs SSY Group's Betahistine Mesilate Tablets for Drug Production, Registration | MT |
05/07 | Chinese Regulator Approves SSY Group's Several Drugs for Production, Registration | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.55% | 163.18Cr | |
+63.05% | 86TCr | |
+38.91% | 63TCr | |
-4.78% | 36TCr | |
+17.52% | 32TCr | |
+8.43% | 30TCr | |
+13.53% | 24TCr | |
+5.15% | 23TCr | |
+16.40% | 23TCr | |
+14.63% | 18TCr |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development